GPhA Study Assails REMS Misuse to Delay Generics

Generic Line
Brand manufacturers who use risk evaluation and mitigation strategies (REMS) to delay generic competition by denying product samples to would-be ANDA filers are costing pharmaceutical payers billions of dollars each year, according to a new study commissioned by GPhA.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00